Needham Reiterates Buy on Cormedix, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix (NASDAQ:CRMD) and maintained a $10 price target.
August 15, 2024 | 9:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix and maintained a $10 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst suggests positive sentiment and confidence in Cormedix's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100